Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018:

an industry analysis of technologies, stakeholders, deals & trends

It is estimated that there are 3-4 times more intracellular targets than surface protein targets. However, these intracellular cancer targets are not accessible to traditional monoclonal antibody (mAb) therapies. Since many of these targets are not enzymes or surface receptoers with readily druggable pockets, these important oncogenic proteins cannot be easily inhibited with small molecules. Thus, intracellular cancer-specific proteins, such as mutated oncogene products, transcription factors, protein adapters, and other nontraditional targets, remain inaccessible to current technologies used for FDA-approved drugs.

Therefore, novel technologies are needed to address historically undruggable targets and complex mechanisms, such as intracellular protein-protein interactions like p53 or Ras, ?-catenin and Myc.



Presentation of Target

Target Examples

Therapeutic Modality

Effector Function

On cell surface as peptide-MHC class I complex

Neoantigens

 

Gp100; NY-ESO-1; MAGE-A, PRAME; WT1; MART-1

TCR fusion protein

 

TCR-like antibody

Fc-enhanced

Bispecific (T-cell recruiting)

Drug Conjugate

Intracellular;

Intranuclear

Protein-protein interaction (PPI)

Beta-catenin; Myc; Ras

Cell penetrating peptide, miniprotein or antibody incl. shuttle

Inhibition

 

This report „Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends“ brings you up-to-date regarding key technologies


  • for identification and validation of intracellular targets,

  • for generation of T-cell receptors (TCR) and TCR fusion proteins,

  • for discovery of TCR-like antibodies, and

  • for construction of cell-penetrating peptides, proteins and antibodies.
The report furthermore describes the profiles of leading product candidates created by these technologies. The technology companies are presented and analyzed. Deals between Big Pharma and technology companies as well as collaboration and licensing deals between technology companies are highlighted. The value of technologies and product candidates are discussed regarding company acquisition prices, economic deal terms and financing rounds.

Download sample pages: Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

What will you find in the report?

Description and comparison of technologies for


  • Discovery and validation of intracellular targets;

  • Discovery and optimization of T-Cell Receptors (TCRs);

  • Generation of TCR-like or TCR-mimic antibodies;

  • Generation of TCR fusion proteins

  • Generation of cell-penetrating peptides, proteins and antibodies.
Presentation and discussion of profiles of selected product candidates:

  • TCRL antibodies and TCR fusion proteins; and

  • Cell-penetrating peptides, miniproteins and single domain and Ig antibodies

Stakeholder analysis based on profiles of 45 companies active in the field

Analysis of partnering deals and financing rounds